rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RNAC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
      Nov 16Yahoo FinanceRNAC
      Cartesian Therapeutics earnings beat by $0.63, revenue topped estimates
      Nov 5Investing.comRNAC
      Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

      Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomy

      Nov 5Yahoo FinanceRNAC
      Cartesian Therapeutics Announces New Employment Inducement Grant
      Nov 3Yahoo FinanceRNAC
      Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement (RNAC)
      Oct 29Seeking AlphaRNAC
      Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Immix Biopharma (IMMX) and Surgery Partners (SGRY)

      Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailIMMXRNACSGRY
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailRNAC
      H.C. Wainwright reiterates Cartesian Therapeutics stock rating at buy
      Sep 30Investing.comRNAC
      Cartesian Therapeutics Announces New Employment Inducement Grants

      FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On September 4, 2026, the Company issued to these employees options to purchase an aggregate of 59,700 shares of the Company’s common stock with an exercise price of $9.27, the closing trading price of the Company’s commo

      Sep 8Yahoo FinanceRNAC
      Cartesian Therapeutics to Participate in Upcoming Investor Conferences

      FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026One-on-one and group investor meetings at Morgan Stanley’s 24th Annual He

      Sep 3Yahoo FinanceRNAC

      This is the newest page. Registered accounts read further back.